CN107970241B - 一种新型酪氨酸激酶抑制剂安罗替尼在制备抑制骨肉瘤的药物中的应用 - Google Patents

一种新型酪氨酸激酶抑制剂安罗替尼在制备抑制骨肉瘤的药物中的应用 Download PDF

Info

Publication number
CN107970241B
CN107970241B CN201810058487.7A CN201810058487A CN107970241B CN 107970241 B CN107970241 B CN 107970241B CN 201810058487 A CN201810058487 A CN 201810058487A CN 107970241 B CN107970241 B CN 107970241B
Authority
CN
China
Prior art keywords
osteosarcoma
cells
nilotinib
application
growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201810058487.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN107970241A (zh
Inventor
华莹奇
王刚阳
蔡郑东
王卓莹
张涛
汪红胜
孙梦熊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority to CN201810058487.7A priority Critical patent/CN107970241B/zh
Publication of CN107970241A publication Critical patent/CN107970241A/zh
Priority to PCT/CN2018/106625 priority patent/WO2019140937A1/zh
Priority to CN201980008849.4A priority patent/CN111683661B/zh
Priority to RU2020124923A priority patent/RU2787235C2/ru
Priority to JP2020540394A priority patent/JP7324759B2/ja
Priority to KR1020207024248A priority patent/KR20200111752A/ko
Priority to EP19740851.1A priority patent/EP3744325B1/en
Priority to ES19740851T priority patent/ES2947685T3/es
Priority to CN202210965476.3A priority patent/CN115337304A/zh
Priority to PCT/CN2019/071846 priority patent/WO2019141170A1/zh
Application granted granted Critical
Publication of CN107970241B publication Critical patent/CN107970241B/zh
Priority to US16/904,338 priority patent/US20200316053A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201810058487.7A 2018-01-22 2018-01-22 一种新型酪氨酸激酶抑制剂安罗替尼在制备抑制骨肉瘤的药物中的应用 Active CN107970241B (zh)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CN201810058487.7A CN107970241B (zh) 2018-01-22 2018-01-22 一种新型酪氨酸激酶抑制剂安罗替尼在制备抑制骨肉瘤的药物中的应用
PCT/CN2018/106625 WO2019140937A1 (zh) 2018-01-22 2018-09-20 一种新型酪氨酸激酶抑制剂-安罗替尼在骨肉瘤的应用
EP19740851.1A EP3744325B1 (en) 2018-01-22 2019-01-16 Application of novel tyrosine kinase inhibitor, anlotinib, in osteosarcoma and chondrosarcoma
RU2020124923A RU2787235C2 (ru) 2018-01-22 2019-01-16 Применение нового ингибитора тирозинкиназ, анлотиниба, при остеосаркоме и хондросаркоме
JP2020540394A JP7324759B2 (ja) 2018-01-22 2019-01-16 新規チロシンキナーゼ阻害剤であるアンロチニブの骨肉腫及び軟骨肉腫への使用
KR1020207024248A KR20200111752A (ko) 2018-01-22 2019-01-16 신규 티로신 키나아제 억제제인 안로티닙의 골육종 및 연골육종에 대한 사용
CN201980008849.4A CN111683661B (zh) 2018-01-22 2019-01-16 一种新型酪氨酸激酶抑制剂-安罗替尼在骨肉瘤和软骨肉瘤的应用
ES19740851T ES2947685T3 (es) 2018-01-22 2019-01-16 Aplicación del nuevo inhibidor de la tirosinacinasa, anlotinib, en osteosarcoma y condrosarcoma
CN202210965476.3A CN115337304A (zh) 2018-01-22 2019-01-16 一种新型酪氨酸激酶抑制剂-安罗替尼在骨肉瘤和软骨肉瘤的应用
PCT/CN2019/071846 WO2019141170A1 (zh) 2018-01-22 2019-01-16 一种新型酪氨酸激酶抑制剂-安罗替尼在骨肉瘤和软骨肉瘤的应用
US16/904,338 US20200316053A1 (en) 2018-01-22 2020-06-17 Application of novel tyrosine kinase inhibitor, anlotinib, in osteosarcoma and chondrosarcoma

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810058487.7A CN107970241B (zh) 2018-01-22 2018-01-22 一种新型酪氨酸激酶抑制剂安罗替尼在制备抑制骨肉瘤的药物中的应用

Publications (2)

Publication Number Publication Date
CN107970241A CN107970241A (zh) 2018-05-01
CN107970241B true CN107970241B (zh) 2020-05-22

Family

ID=62006233

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201810058487.7A Active CN107970241B (zh) 2018-01-22 2018-01-22 一种新型酪氨酸激酶抑制剂安罗替尼在制备抑制骨肉瘤的药物中的应用
CN202210965476.3A Pending CN115337304A (zh) 2018-01-22 2019-01-16 一种新型酪氨酸激酶抑制剂-安罗替尼在骨肉瘤和软骨肉瘤的应用
CN201980008849.4A Active CN111683661B (zh) 2018-01-22 2019-01-16 一种新型酪氨酸激酶抑制剂-安罗替尼在骨肉瘤和软骨肉瘤的应用

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202210965476.3A Pending CN115337304A (zh) 2018-01-22 2019-01-16 一种新型酪氨酸激酶抑制剂-安罗替尼在骨肉瘤和软骨肉瘤的应用
CN201980008849.4A Active CN111683661B (zh) 2018-01-22 2019-01-16 一种新型酪氨酸激酶抑制剂-安罗替尼在骨肉瘤和软骨肉瘤的应用

Country Status (6)

Country Link
EP (1) EP3744325B1 (https=)
JP (1) JP7324759B2 (https=)
KR (1) KR20200111752A (https=)
CN (3) CN107970241B (https=)
ES (1) ES2947685T3 (https=)
WO (2) WO2019140937A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107970241B (zh) * 2018-01-22 2020-05-22 正大天晴药业集团股份有限公司 一种新型酪氨酸激酶抑制剂安罗替尼在制备抑制骨肉瘤的药物中的应用
US11419862B2 (en) 2018-03-14 2022-08-23 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Quinoline derivative for treatment of nasopharyngeal carcinoma
CN112105620B (zh) * 2018-05-25 2026-02-24 正大天晴药业集团股份有限公司 用于治疗肺癌的tlr7激动剂及其药物组合
WO2020187152A1 (zh) * 2019-03-15 2020-09-24 正大天晴药业集团股份有限公司 治疗小细胞肺癌的联用药物组合物
CN111821459A (zh) * 2019-04-17 2020-10-27 正大天晴药业集团股份有限公司 用于联合治疗骨肉瘤的喹啉类化合物
CN111821302A (zh) * 2019-04-18 2020-10-27 正大天晴药业集团股份有限公司 用于联合治疗软骨肉瘤的喹啉类化合物
JP7611855B2 (ja) * 2019-04-19 2025-01-10 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド ユーイング肉腫治療用キノリン系化合物又はその薬学的に許容される塩
AU2020273687B2 (en) 2019-05-10 2025-07-24 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Quinoline derivative used for soft tissue sarcoma combination therapy
WO2020233723A1 (zh) * 2019-05-23 2020-11-26 正大天晴药业集团股份有限公司 用于治疗头颈癌的喹啉衍生物
CN114761010B (zh) * 2019-11-25 2024-04-16 正大天晴药业集团股份有限公司 喹唑啉衍生物或其盐的联用药物组合物及其用途
CN112043698B (zh) * 2020-08-03 2023-04-25 吴宏伟 一组小分子药物在制备抑制肉瘤药物中的应用
CN113456797B (zh) * 2021-06-18 2024-03-08 暨南大学 长春碱类衍生物在制备治疗骨肉瘤和/或软组织肉瘤药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3120851A1 (en) * 2015-07-21 2017-01-25 Pangaea Biotech S.L. 4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8h)-one for treatment of solid cancers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8148532B2 (en) * 2007-03-14 2012-04-03 Guoqing Paul Chen Spiro substituted compounds as angiogenesis inhibitors
CN105311030B (zh) 2014-06-06 2020-03-24 正大天晴药业集团股份有限公司 用于抗肿瘤的螺取代化合物
CN105311029A (zh) 2014-06-06 2016-02-10 正大天晴药业集团股份有限公司 抗肿瘤活性的喹啉衍生物
US9751859B2 (en) 2015-05-04 2017-09-05 Advenchen Pharmaceuticals, LLC Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine, its crystalline form and its salts
US10709708B2 (en) * 2016-03-17 2020-07-14 The University Of North Carolina At Chapel Hill Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
CN107970241B (zh) * 2018-01-22 2020-05-22 正大天晴药业集团股份有限公司 一种新型酪氨酸激酶抑制剂安罗替尼在制备抑制骨肉瘤的药物中的应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3120851A1 (en) * 2015-07-21 2017-01-25 Pangaea Biotech S.L. 4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8h)-one for treatment of solid cancers

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
李晓琴等.骨肉瘤中C-kit受体和血小板衍生生长因子受体-α的表达及意义.《临床与实验病理学杂志》.2013,第29卷(第08期),第870页右栏第2段. *
软组织肉瘤分子靶向治疗研究进展;高天等;《中国肿瘤临床》;20170115;第44卷(第01期);第9页左栏第25-40行 *
骨肉瘤中C-kit受体和血小板衍生生长因子受体-α的表达及意义;李晓琴等;《临床与实验病理学杂志》;20130828;第29卷(第08期);第870页右栏第2段 *

Also Published As

Publication number Publication date
KR20200111752A (ko) 2020-09-29
WO2019141170A1 (zh) 2019-07-25
ES2947685T3 (es) 2023-08-16
EP3744325B1 (en) 2023-06-07
CN111683661A (zh) 2020-09-18
CN107970241A (zh) 2018-05-01
EP3744325A1 (en) 2020-12-02
CN115337304A (zh) 2022-11-15
JP7324759B2 (ja) 2023-08-10
JP2021510725A (ja) 2021-04-30
RU2020124923A3 (https=) 2022-04-26
CN111683661B (zh) 2022-07-26
EP3744325A4 (en) 2021-10-20
RU2020124923A (ru) 2022-02-24
WO2019140937A1 (zh) 2019-07-25

Similar Documents

Publication Publication Date Title
CN107970241B (zh) 一种新型酪氨酸激酶抑制剂安罗替尼在制备抑制骨肉瘤的药物中的应用
Jena et al. TGF-β1 induced autophagy in cancer associated fibroblasts during hypoxia contributes EMT and glycolysis via MCT4 upregulation
Rios-Fuller et al. Ganoderma lucidum extract (GLE) impairs breast cancer stem cells by targeting the STAT3 pathway
Xia et al. Dihydroartemisinin inhibits the proliferation of IgAN mesangial cells through the mTOR signaling pathway
Xu et al. Blockade of autophagy aggravates endoplasmic reticulum stress and improves Paclitaxel cytotoxicity in human cervical cancer cells
He et al. Casticin inhibits self-renewal of liver cancer stem cells from the MHCC97 cell line
Li et al. Inhibitory effect of berberine on human skin squamous cell carcinoma A431 cells
Hasenoehrl et al. Anti-tumor effects of shikonin derivatives on human medullary thyroid carcinoma cells
Cui et al. Tanshinone I inhibits metastasis of cervical cancer cells by inducing BNIP3/NIX-mediated mitophagy and reprogramming mitochondrial metabolism
CN106236762A (zh) 松果菊苷和麦角甾苷的新用途
Yang et al. Huaier aqueous extract inhibits proliferation and metastasis of tuberous sclerosis complex cell models through downregulation of JAK2/STAT3 and MAPK signaling pathways
Wang et al. Rapamycin inhibits B16 melanoma cell viability in vitro and in vivo by inducing autophagy and inhibiting the mTOR/p70‑S6k pathway
El Haddaoui et al. Rintatolimod: a potential treatment in patients with pancreatic cancer expressing Toll-like receptor 3
CN112353797B (zh) 吲哚-3-乙腈在制备治疗或预防流感病毒感染的药物中的应用
Wang et al. Epirubicin inhibits growth and alters the malignant phenotype of the U‑87 glioma cell line
CN108303552A (zh) 青藤碱对胰腺癌细胞系sw1990增殖凋亡的检测方法
Wang et al. Effects and mechanism of siomycin A on the growth and apoptosis of MiaPaCa-2 cancer cells
CN116370483A (zh) 泽泻醇b在抗鼻咽癌药物制备中的应用
CN114652731B (zh) 单宁酸在制备防治非洲猪瘟药物中的应用
CN108998495A (zh) 一种抗乳腺癌药物的高通量筛选方法
Jiang et al. Oridonin inhibits SGIV infection by regulating glycolipid metabolism and inflammatory response
Li et al. Quinacrine induces autophagy via the Dlg5/AKT pathway to inhibit osteosarcoma cell proliferation and suppresses migration and invasion through the Dlg5/Girdin pathway
CN116173011B (zh) 一种靶向slc11a2的抑制剂及其应用
US11925628B2 (en) Applications for nicardipine in preparing anti-lung cancer products
CN118634226A (zh) 艾培替尼和吉非替尼在治疗egfr-tki耐药非小细胞肺癌中的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20181206

Address after: No. 369, Yuzhou South Road, Lianyungang, Jiangsu Province

Applicant after: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Address before: No. 100 Haining Road, Hongkou District, Shanghai 200080

Applicant before: No.1 People's Hospital Shanghai City

GR01 Patent grant
GR01 Patent grant